BioSpace News Archive

MediWound Ltd., a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, announced it has gained marketing approval of NexoBrid® in India.

Rockwell Medical, Inc., a commercial healthcare company focused on providing life-sustaining products for patients suffering from blood disorders and diseases associated with the kidney, announced that the Company is adding new business within the Minnesota region.

Visiongain has published a new report entitled Alzheimer’s Therapeutics 2022-2032.

European Commission approves SPEVIGO ® (spesolimab) for generalized pustular psoriasis flares.

Lilly expects to deliver strong financial and operational performance in 2023, highlighted by volume-driven revenue growth; potential launches for donanemab, mirikizumab, lebrikizumab and pirtobrutinib; potential regulatory submissions for tirzepatide in obesity; and numerous other anticipated pipeline advancements.

Rapid Therapeutics Science Laboratories announces today that it has moved three (3) proprietary pharmaceutical grade patents from provisional to non-provisional status.

EVOQ Therapeutics, Inc. today announced a collaboration with JDRF for the development of a new drug platform for antigen-specific immune-tolerizing therapy against Type 1 diabetes (T1D).

Terray Therapeutics today announced that John Maraganore, Ph.D., former founding CEO of Alnylam Pharmaceuticals, has been appointed as Strategic Advisor to the Board of Directors and Leadership Team.

Efemoral Medical , developer of advanced interventional bioresorbable therapies, today announced the closing of its $4.9M preferred Series A1 round.

Enzolytics, Inc. (OTC PINK:ENZC) ( https://enzolytics.com/ ). Enzolytics’ focus is on the production and distribution of the Company’s therapeutics and advancing its research and development programs.